Short answer
LEMAITRE VASCULAR INC (LMAT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Preliminary financial and operational results announced for quarter ended September 30, 2026.
LEMAITRE VASCULAR INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary financial and operational results announced for quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for the company’s reported quarterly figures and operating updates
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $68.0mm, up 11% reported and 12% organically, led by grafts up 20% and shunts up 14%
- GAAP EPS $0.65, down 14%, but adjusted EPS $0.65, up 5% after excluding the 2025 tax-credit benefit
- B. Braun vascular asset acquisition for $19.2mm expands the portfolio, with sales transition over 18-24 months
- Full-year 2026 guidance: sales midpoint $275.8mm, operating income $75.4mm, EPS $2.80
- Quarterly dividend increased to $0.25 per share, payable December 3, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LEMAITRE VASCULAR INC 8-K filings
Get the next LMAT 8-K as it lands
Follow LMAT for push alerts, or ask the research agent what this filing means.